David T. Woodley

Allergy and Immunology

1450 San Pablo St Ste 2000
Los Angeles, CA 90033

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Targeting Hsp90 in Cancer for 25 Years: Failure of Previous Clinical Trials and New Hope for Future Therapeutics.

Targeting Hsp90 in Cancer for 25 Years: Failure of Previous Clinical Trials and New Hope for Future Therapeutics.

Journal: Cells

Published: November 21, 2025

Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough.

Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough.

Journal: Cells

Published: June 17, 2025

Pseudopemphigoid: A systematic review.

Pseudopemphigoid: A systematic review.

Journal: JAAD international

Published: November 11, 2024

Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa.

Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 19, 2024

Discovery of Cell Number-Interstitial Fluid Volume (CIF) Ratio Reveals Secretory Autophagy Pathway to Supply eHsp90α for Wound Healing.

Discovery of Cell Number-Interstitial Fluid Volume (CIF) Ratio Reveals Secretory Autophagy Pathway to Supply eHsp90α for Wound Healing.

Journal: Cells

Published: June 11, 2024

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials.

Previously unrecognized and potentially consequential challenges facing Hsp90 inhibitors in cancer clinical trials.

Journal: Cell stress & chaperones

Published: May 27, 2024

Correction: Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression.

Correction: Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression.

Journal: Oncogene

Published: April 04, 2024

Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial.

Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial.

Journal: The British journal of dermatology

Published: December 15, 2023

Expression of Concern: Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90α autocrine signaling to promote keratinocyte migration.

Expression of Concern: Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90α autocrine signaling to promote keratinocyte migration.

Journal: Journal of cell science

Published: November 06, 2023

Why Are There So Few FDA-Approved Therapeutics for Wound Healing?

Why Are There So Few FDA-Approved Therapeutics for Wound Healing?

Journal: International journal of molecular sciences

Published: August 31, 2023

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.

Journal: The Journal of investigative dermatology

Published: March 23, 2023

COVID-19 and autoimmune bullous diseases: Lessons learned.

COVID-19 and autoimmune bullous diseases: Lessons learned.

Journal: Autoimmunity reviews

Published: January 09, 2023

Showing 1-12 of 82

Last Updated: 09/26/2026